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Does a low haematocrit increase 
bleeding?
There has been a suggestion that a low haematocrit 
contributes towards coagulopathy. Iselin et al examined 
in vitro isolated low haematocrit and bleeding tendency.1 
Using a normal platelet count, clotting factors, and a low 
haematocrit, they tested the viscoelastic properties with 
a thromboelastogram (TEG®). Their results reflected an 
increase in coagulability in keeping with the properties of a 
crystalloid solution which they used in the reconstitution of a 
lower hematocrit. Darlington et al found a strong correlation 
between a low haemoglobin, platelet count and fibrinogen 
level with bleeding.2 
Point-of-care devices
It takes at least 30 minutes for results to be obtained 
with laboratory coagulation assessment tests. Plasma is 
used to evaluate whole blood and endothelial processes. 
The newer point-of-care devices, ROTEM® and TEG®, 
assess the viscoelastic processes of coagulation by 
thromboelastometry and thromboelastography.3-6 
The ROTEM®, by using different types of new reagents, 
can  be used to evaluate the intrinsic pathway (INTEM®), the 
extrinsic pathway (EXTEM®), fibrinogen activity (FIBTEM®), 
heparin activity (HEPTEM®) and aprotinin effect (APTEM®). 
Thrombocytopenia can be diagnosed with the EXTEM®-A. 
The TEG®, with an interpretation of the maximum amplitude, 
reation time, coagulation time and clot strength, can be 
used to evaluate platelet function, factor activity and clot 
lysis.3-5 The Multiplate®, a TEG® modification, can be used 
for platelet mapping to measure platelet aggregation in 
antiplatelet therapy. The VerifyNow® measures the platelet 
reactivity degree in patients undergoing treatment.4,5 These 
tests cannot be used to predict postoperative bleeding, 
but can be used to diagnose and guide treatment of the 
underlying cause of coagulopathy.
Fibrinogen concentrate, prothrombin 
complex concentrates and recombinant 
factor VII 
Fresh frozen plasma (FFP) contains ± 250 mg in 100 ml of 
fibrinogen, while cryoprecipitate contains ± 225 mg in 15 ml 
(1 g of fibrinogen in five units of cryoprecipitate). Fibrinogen 
concentrate has a predictable dose per vial with a long shelf 
life (900-1 300 mg/vial), less side-effects and is not blood 
group-specific.5-9 A dose of 7.6-mg/kg fibrinogen is needed 
to increase the FIBTEM® by 1 mm.3,4 
Prothrombin complex concentrates (PCCs) are produced 
in 3-factor and 4-factor formulations. The 4-factor PCC 
contains factor VII additionally to factor II, IX and X. 
Recombinant factor VIIa was licensed to treat haemophilia 
patients with antibodies. It is widely used off label for massive 
haemorrhage from surgery and anticoagulants. It can be 
used in combination with 3-factor PCC.5-9 Thromboembolic 
phenomena and thrombosis are common side-effects.
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Abstract
This manuscript serves to highlight some novel approaches to perioperative coagulation abnormalities and to address 
unanswered questions.
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Pharmacological procoagulation therapy
The protamine prescription for the reversal of heparin often 
overlooks the elimination and metabolism factor.10-11 More 
than adequate amounts of protamine lead to increased 
bleeding. Although protamine has been postulated to 
activate platelets, affect clot initiation time and clot kinetics, 
the real mechanism is not fully known. Ainle et al have 
suggested that it downregulates thrombin generation by 
inhibition of factor V activation.11  
Tranexamic Acid Epsilon Aminocaproic Acid (EACA) are 
used to treat hyperfibrinolysis by competitively inhibiting 
the conversion of plasminogen into plasmin. Tranexamic 
acid is available orally, as a mouthwash and in intravenous 
preparations.12 The oral dose is 15-30 μg/kg given two 
hours preoperatively, and every 6-8 hours over 7-10 days. 
Desmopressin Acetate (DDAVP®) stimulate the endogenous 
release of von Willebrand factor and factor VIII in 
patients with haemophilia A and von Willebrand disease. 
It has no effect on patients with haemophilia B.12,13 It 
can be used subcutaneously or intravenously in doses of 
3 μg/kg one hour pre-procedure intranasally in a dose of 
150 μg in a 50-kg patient, and 150 μg in each nostril in a 
≥ 50-kg patient. Fluid restriction in 24-hour post-
administration assists with a reduction in the risk of 
hyponatremia. DDAVP® may cause tachycardia, headaches, 
abdominal cramps and hypotension.   
Premarin®  increases levels of fibrinogen and fibrinogen 
activity and increases plasminogen antigen and activity. 
It was shown to reduce the volume of postoperative 
bleeding by 37% (ml/kg), when compared to the control 
group, without any complications in paediatric patients 
undergoing scoliosis surgery.14 Premarin® was shown to 
reduce bleeding to 50% below pretreatment values over a 
few days in patients with renal failure, platelet dysfunction 
and clinical bleeding.
Aprotinin is now only used in patients at very high risk of 
bleeding owing to the risk of cardiovascular events observed 
during the Blood Conservation Using Antifibrinolytics in a 
Randomised Controlled Trial.12 More research is underway 
to examine these facts closely.
Local haemostatic mechanisms in the form of tissue glues, 
include Surgicel®, Gelfoam®, Lyostpt® and Ankaferd Blood 
Stopper®.15 Newer bioagents are entering the market.16
Anticoagulants in the perioperative 
period
Warfarin should be stopped seven days preoperatively 
and recommenced soon postoperatively if there is no risk 
of bleeding.5-9,17 FFP (10-30 ml/kg) is used to reverse the 
effects of warfarin. With the use of point-of-care devices, 
PCC dosages can be used more predictably. Four-factor 
PCC (25 IU/kg) can be used if EXTEM®-CT is > 80 seconds 
or TEG® R-time is > 10 seconds. 
Unfractionated heparin has a half life of 40 minutes. It is 
traditionally monitored using activated thromboplastin time 
(APTT) or activated clotting time.18 Low-molecular-weight 
heparin (LMWH) has an anti-factor Xa to anti-factor IIa 
ratio of up to 4:1 in commercial preparations. It cannot be 
monitored with the use of APTT.18 The HEPTEM®-directed 
protamine administration is an option.
Antiplatelet drugs
Clopidogrel has a half-life of four hours, but has to be 
stopped 5-7 days preoperatively because of irreversible 
platelet inhibition.18,19 The glycoprotein IIb/IIIa agents 
have short half-lives, with a return to > 50% of platelet 
activity ranging from 4-48 hours, allowing bridging therapy 
after the cessation of clopidogrel. EXTEM®-A-measured 
thrombocytopenia (< 40-mm) and TEG-Max® (< 50-mm) 
guided platelet transfusion can be used as guided antidote 
therapy.18,19 
Thrombin inhibitors
Rivaroxaban has a renal clearance of 80% and a half-life 
of 14-17 hours. Thrombin time is a sensitive monitor of 
antithrombin activity, although it is not accurate with extreme 
dosages.18,20 There is a curvilinear relationship between 
dabigatran and APTT. International normalised ratio (INR) 
is also not useful. The Hemoclot® direct thrombin inhibitor 
assay has been used for the quantitative measurement of 
dabigatran. Ecarin clotting time, although it has limitations, 
can also be used to measure the activity of direct thrombin 
inhibitors.20 Gastric lavage, activated charcoal and dialysis 
can be utilised in emergency situations. Recombinant factor 
VIIa (1 mg/kg) or activated PCC (40-80 U/kg) might have 
antidote activity.
Factor Xa inhibitors, rivaroxaban and apixaban, have half-
lives ranging from 7-14 hours, and APTT cannot be used 
to monitor them. Prothrombin time correlates with the 
plasma concentrations of rivaroxaban, while INR relates 
in a dose-dependent manner with apixaban.21 The plasma 
concentration of factor Xa inhibitors can be measured by 
assays of factor Xa activity. Four-factor PCC at a dosage of 
50 IU/kg can be used to reverse effects.21
Bleeding in the trauma patient
The use of a “coagulation box” by Hilbert et al resulted 
in massive amounts of blood products needing to be 
used in a haemoglobin-driven algorithm, with a high 
mortality outcome.22 This study is in clear contrast with 
the blood conservation principles advocated by both the 
Society of Thoracic Surgeons/Society of Cardiovascular 
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Anesthesiologists and European guidelines.18,23 The APTEM® 
can be used to measure hyperfibrinolysis associated 
with massive bleeding, whereas the EXTEM®-A measures 
thrombocytopenia.3-6 The hypofibrinogenemia, which 
follows massive bleeding, can be shown on the FIBTEM® 
or with kaolin-TEG® α angle < 52 degrees. The Multiplate® 
showed that platelet aggregation induced by collagen was 
lower in high bleeding patients.3-6 The debate continues as 
to whether or not a higher FFP to packed red blood cell 
ratio should be used. The military results of early plasma 
and platelet transfusion are promising.24-26
Bleeding in cardiovascular patients
There are multifactorial causes of coagulation problems 
in cardiovascular patients. Fibrinogen is the first to reach 
critically low levels in the perioperative period, with a 
decrease of up to 40%. FFP, cryoprecipitate or fibrinogen 
concentrate, up to doses of 6-7 g, guided by FIBTEM®-CF, 
increases of 1 mm per 7.6-mg/kg fibrinogen dose, is used. 
Four-factor PCC (25 IU/kg) can be used if EXTEM®-CT is 
> 80 seconds or TEG® R-time is > 10 seconds.5,6,9,12,18-21,27 
The FIBTEM®, as guidance towards transfusion in one 
study, reduced the number of units used, sevenfold (2.5 vs. 
16.4 units).5,6,9,12,18-21,27 
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